Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Analytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant

Hiromichi Suzuki a,b,c,*, Yusaku Akashi b,c,d, Daisuke Kato e, Yuto Takeuchi a,b, Yoshihiko Kiyasu a,b,c, Norihiko Terada b,c, Yoko Kurihara a, Miwa Kuwahara e, Shino Muramatsu e, Atsuo Ueda f, Shigeyuki Notake f, Koji Nakamura f

a Department of Infectious Diseases, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki, 305-8576, Japan
b Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital, I-3-1 Amakubo Tsukuba, Ibaraki, 305-8558, Japan
c Department of Infectious Diseases, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
d Akashi Internal Medicine Clinic, 3-1-63 Ashiagoka, Kashiwara, Osaka, 582-0026, Japan
e Denka Co., Ltd. Gosen Site, Research & Development Division, Reagent R&D Department, 1-2-2 Minami-hun-cho, Gosen-shi, Nigata, 959-1695, Japan
f Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki, 305-8558, Japan

ARTICLE INFO

Keywords:
Nasopharyngeal sample
SARS-CoV-2
COVID-19
Omicron variant
QuickNavi-COVID19 Ag

ABSTRACT

Introduction: Rapid qualitative antigen testing is essential in the clinical management of COVID-19. However, most evaluations of antigen tests have been performed before the emergence of the Omicron variant.

Methods: This prospective observational study evaluated QuickNavi-COVID19 Ag, a rapid antigen detection test between December 2021 and February 2022 in Japan, using real-time reverse transcription (RT)-PCR as a reference. Two nasopharyngeal samples were simultaneously collected for antigen testing and for RT-PCR. Variant analysis of the SARS-CoV-2 genomic sequencing was also performed.

Results: In total, nasopharyngeal samples were collected from 1073 participants (417 positive; 919 symptomatic; 154 asymptomatic) for analysis. Compared with those of RT-PCR, the sensitivity, specificity, positive predictive value, and negative predictive value were 94.2% (95% CI: 91.6%–96.3%), 99.5% (95% CI: 98.7%–99.9%), 99.2% (95% CI: 97.8%–99.8%), and 96.5% (95% CI: 94.8%–97.7%), respectively. The sensitivity among asymptomatic individuals was 94.3% (95% CI: 91.5%–96.4%). Overall, 85.9% of sequences were classified as Omicron sublineage BA.1, 12.4% were Omicron sublineage BA.2, and 1.6% were Delta B.1.617.2 (Delta variant). Most of the samples (87.1%) had Ct values of <25, and the sensitivity was 47.4% for low viral load samples (Ct ≥ 30); a similar trend was observed in both symptomatic and asymptomatic groups.

Conclusions: The QuickNavi-COVID19 Ag test showed sufficient diagnostic performance for the detection of the SARS-CoV-2 Omicron sublineages BA.1 and BA.2 from nasopharyngeal samples. However, the current study was mainly performed in symptomatic patients and the results are not sufficiently applicable for asymptomatic patients.

1. Introduction

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529, i.e., the Omicron variant, dramatically increased the clinical cases of coronavirus disease 2019 (COVID-19). Owing to its high transmissibility, short incubation period [1–4] and reduced vaccine efficacy [5,6], the Omicron variant sublineages BA.1 and BA.2 became predominant worldwide by early 2022 [7]. Compared with previously dominant variants, COVID-19 caused by the Omicron variant is less likely to damage the lung [8] and more frequently causes sore throat and a hoarse voice [9]. Qualitative antigen tests that use immunochromatography are a useful point-of-care diagnostic testing method for infectious diseases because of their low cost, simple procedure, high availability of the test
device, and short analytical time. For the laboratory diagnosis of COVID-19, antigen testing has been recommended for both symptomatic and asymptomatic individuals who are at high risk of infection, especially in situations where the prevalence of SARS-CoV-2 is $\geq 5\%$ or where nucleic acid amplification test capacity is limited [10]. The diagnostic performance of antigen testing had been presumed to be preserved for the Omicron variant [7]. However, a significant impairment of sensitivity to the Omicron variant has been reported for nine antigen tests [11,12].

Herein, we prospectively evaluated the diagnostic performance of a qualitative antigen test (QuickNavi-COVID19 Ag, Denka Co., Ltd., Tokyo, Japan) using nasopharyngeal swab samples. We also conducted a genomic sequencing analysis to identify SARS-CoV-2 variants.

1.1. Patients and methods

This study was conducted between December 28, 2021 and February 16, 2022. Sample collection and antigen testing were performed at a drive-through sample collection point at Tsukuba Medical Center Hospital (TMCH), and PCR was performed in the TMCH microbiology department. TMCH provides SARS-CoV-2 testing for the Tsukuba district in Japan. People with and without symptoms were referred from 65 clinics and a local public health center. All asymptomatic individuals had a history of contact with a confirmed or suspected COVID-19 case.

Informed consent was verbally obtained from all participants and was documented in their electronic medical record to prevent infection transmission, written informed consent was not obtained. The ethics board of the University of Tsukuba Hospital approved the study (approval number: R03-042), including the method of obtaining informed consent.

1.2. Study process

Two nasopharyngeal samples were separately collected by medical professionals one for RT-PCR and the other for antigen testing, as previously described [13–20]. A nasopharyngeal sample was obtained from each nasal cavity. All antigen tests were immediately performed on site after sample collection. A swab was inserted into a specimen buffer tube, and three drops of the prepared specimen were added on the test device. The sample processing time was 8 min, and the result was analyzed visually by the personnel who collected the sample.

For RT-PCR, a swab was diluted in 3 mL of Universal Transport Medium (Copan Italia S.p.A., Brescia, Italy) on site, and the sample was transferred to the TMCH microbiology department for in-house RT-PCR testing [13,21]. A 200 μL aliquot of each nasopharyngeal sample was extracted with a magLeAD 6gC (Precision System Science Co., Ltd., Chiba, Japan), and 100 μL of purified sample was eluted. The eluted samples were transferred to Denka Co., Ltd. For reference real-time RT-PCR testing to identify SARS-CoV-2, we used a method developed by the National Institute of Infectious Diseases (NIID), Japan. This method used an Applied Biosystems QuantStudio 3 (Thermo Fisher Scientific Inc., Waltham, MA, USA) with a QuantiTect probe RT-PCR kit (Qiagen Inc., Germantown, MD, USA) and a primer/probe N and N2 set [22]. Until the evaluation, all samples were preserved at −80 °C. In case of discrepancy between the in-house PCR and the NIID method results for the presence or absence of SARS-CoV-2, additional examinations with the Xpert Xpress SARS-CoV-2 and GeneXpert system (Cepheid, Sunnyvale, CA, USA) [23] were performed, and those results were used as the final judgment.

1.3. SARS-CoV-2 variant analysis

Of the 393 RT-PCR and QuickNavi-COVID19 Ag positive samples, 185 samples with high viral load (Ct $\leq 21$) were subjected to genomic sequencing analysis. RNAs of 185 samples were extracted using QIAGEN Viral RNA mini kit and sent to Denka Co., Ltd. Denka Co., Ltd. then sent the RNA to iLAC Inc. (Ibaraki, Japan) requesting to perform Next-Generation Sequencing (NGS) and the SARS-CoV-2 variant analysis. NGS was performed using Illumina’s COVIDSeq test and IDT for Illumina-PCR indexes Sets 1–4 (Illumina, San Diego, CA, USA) to prepare sequencing libraries. Sequencing runs were performed on the prepared libraries using Illumina Novaseq 6000 sequencer and NovaSeq 6000 SP Reagent Kit ver1.5. Sequencing results were then analyzed for SARS-CoV-2 variants using Illumina’s DRAGEN COVIDSeq Test Pipeline.

1.4. Statistical analyses of the rapid antigen test

The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the antigen tests were calculated with 95% confidence intervals (CIs).

The sensitivity stratified by the cycle threshold (Ct) value based on the N2 set of the NIID method was also evaluated. All statistical analyses were conducted using R 4.1.2 software (R Foundation, Vienna, Austria) with the “readxl,” “tidyverse,” and “epiR” packages.

2. Results

Nasopharyngeal samples were collected from 1073 participants during the study period; 919 were from symptomatic individuals and 154 were from asymptomatic individuals. For symptomatic participants, the median duration from symptom onset to sample collection was 2 days (interquartile range: 1–3 days).

Of the 1073 samples, 411 were SARS-CoV-2 positive by RT-PCR with the NIID method. There were six discords between the NIID and in-house RT-PCR results. Of the six discordant samples, all were SARS-CoV-2 positive when analyzed by the GeneXpert® system. Consequently, 417 samples (38.9%) were considered to be positive. The positive rate was similar to that of Ibaraki prefecture during the study period, which is available at the prefecture’s web site [24].

The QuickNavi-COVID19 Ag results are shown in Table 1. The sensitivity, specificity, PPV, and NPV were 94.2% (95% CI: 91.6%–96.3%), 99.5% (95% CI: 98.7%–99.9%), 99.2% (95% CI: 97.8%–99.8%), and 96.5% (95% CI: 94.8%–97.7%), respectively. For symptomatic individuals (Table 2a), the sensitivity was 94.3% (95% CI: 91.5%–96.4%) and the specificity was 99.8% (95% CI: 99.0%–100%). For asymptomatic individuals (Table 2b), the sensitivity was 93.1% (95% CI: 77.2%–99.2%) and the specificity was 98.4% (95% CI: 94.3%–99.8%).

The antigen test sensitivities stratified by Ct value (N2) are shown in Table 3–a (all samples), Table 3–b (samples in symptomatic individuals) and Table 3–c (samples in asymptomatic individuals). The percentages of samples with Ct values of $\leq$25 were 88.6% for overall individuals, 88.8% for symptomatic individuals and 85.7% for asymptomatic individuals, respectively. For all samples (Table 3–a), the sensitivities of Ct values of $\leq$20, 20–24, 25–29, and $\geq$30 were 98.9% (95% CI: 96.1%–99.9%), 97.8% (95% CI: 94.4%–99.4%), 85.7% (95% CI: 67.3%–96.0%), and 47.4% (95% CI: 24.4%–71.1%), respectively. For samples in symptomatic individuals (Table 3–b), the sensitivities of Ct values of $\leq$20, 20–24, 25–29, and $\geq$30 were 98.9% (95% CI: 95.9%–99.9%), 97.6% (95% CI: 93.9%–99.3%), 84.0% (95% CI: 63.9%–95.5%), and 50.0% (95% CI: 26.0%–74.0%), respectively. For samples in

| Table 1 | Sensitivity and specificity of the QuickNavi-COVID19 Ag test among all samples. |
|---------|---------------------------------|
| Antigen test | Positive | Negative |
| Antigen test | 393 | 3 |
| Sensitivity (%) | 94.2 (91.6–96.3) |
| Specificity (%) | 99.5 (98.7–99.9) |
Table 2a
Sensitivity and specificity of the QuickNavi-COVID19 Ag test among asymptomatic individuals.

| Antigen test | Positive | Negative |
|--------------|----------|----------|
| Positive     | 96.9 (96.1–99.9) | 2 \quad 1 |
| Negative     | 93.1 (77.2–99.2) | 4 \quad 123 |
| Sensitivity (%) | 94.3 (91.5–96.4) | 9.8 (99.0–99.8) |
| Specificity (%) | 98.4 (94.3–99.8) | 99.8 |

RT-PCR, reverse transcription-polymerase chain reaction.

Table 2b
Sensitivity and specificity of the QuickNavi-COVID19 Ag test among asymptomatic individuals.

| Antigen test | Positive | Negative |
|--------------|----------|----------|
| Positive     | 27 \quad 2 |
| Negative     | 93.1 (77.2–99.2) | 123 |
| Sensitivity (%) | 98.4 (94.3–99.8) | 99.8 |

RT-PCR, reverse transcription-polymerase chain reaction.

Table 3-a
Sensitivity of QuickNavi-COVID19 Ag test stratified by Ct values among all samples.

| Ct values (N2) | Sensitivity (%) | Positive | Negative |
|----------------|-----------------|----------|----------|
| <20            | 98.9 (95.9–99.9) | 181 \quad 2 |
| 20–24          | 97.6 (93.9–99.3) | 177 \quad 4 |
| 25–29          | 84.0 (63.9–95.5) | 24 \quad 4 |
| ≥30            | 50.0 (26.0–74.0) | 9 \quad 9 |

Ci, cycle threshold.

Table 3-b
Sensitivity of QuickNavi-COVID19 Ag test stratified by Ct values among samples in asymptomatic individuals.

| Ct values (N2) | Sensitivity (%) | Positive | Negative |
|----------------|-----------------|----------|----------|
| <20            | 98.9 (95.9–99.9) | 173 \quad 2 |
| 20–24          | 97.6 (93.9–99.3) | 161 \quad 4 |
| 25–29          | 84.0 (63.9–95.5) | 21 \quad 4 |
| ≥30            | 50.0 (26.0–74.0) | 9 \quad 9 |

Ci, cycle threshold.

Table 3-c
Sensitivity of QuickNavi-COVID19 Ag test stratified by Ct values among samples in asymptomatic individuals.

| Ct values (N2) | Sensitivity (%) | Positive | Negative |
|----------------|-----------------|----------|----------|
| <20            | 100 (63.1–100)  | 8 \quad 0 |
| 20–24          | 100 (79.4–100)  | 16 \quad 0 |
| 25–29          | 100 (29.2–100)  | 3 \quad 0 |
| ≥30            | 0 (0–97.5)      | 0 \quad 1 |

Ci, cycle threshold.

am asymptomatic individuals (Table 3-c), the sensitivities of Ct values of <20, 20–24, 25–29, and ≥30 were 100%, 95% (95% CI: 63.1–100%), 100% (95% CI: 79.4–100%), and 0% (95% CI: 0–97.5%), respectively. Detailed information regarding the 24 patients with which false-negative results were obtained with the QuickNavi-COVID19 Ag test are summarized in Table 4. Low viral load samples (Ct ≥ 30) were observed in 14 out of 24 samples (58.3%). 4 samples that were negative by the NIID method were positive only by the GeneXpert system.

The positive rate of the QuickNavi-COVID19 Ag test stratified by the days from the onset of symptoms to sample collection is summarized in Fig. 1. The positive rates were 93.8% (day 0), 93.1% (day 1), 97.6% (day 2), 95.1% (day 3), 93.2% (day 4–6), 71.4% (day 7–9) and 66.7% (day >10).

The SARS-CoV-2 genome analysis results are shown in Fig. 2. Of the 185 samples, 140 (75.7%) were determined to be BA.1.1.2, 21 (11.4%) were BA.2.3, 13 (7.0%) were BA.1.1.3, 3 (1.6%) were BA.1, 3 (1.6%) were BA.2.3, 2 (1.1%) were BA.1.1.1, 2 (1.1%) were BA.2 and 1 (0.5%) was BA.1.15. Overall, 85.9% of the samples were classified as Omicron variant sublineage BA.1, 12.4% were Omicron variant sublineage BA.2, and 1.6% were Delta variant BA.1.617.2.

3. Discussion

In this study, more than 90% of individuals who were PCR positive for SARS-CoV-2 were correctly identified by rapid antigen testing. The current investigation showed that the QuickNavi-COVID19 Ag test has sufficient sensitivity for the detection of Omicron BA.1 and BA.2 from nasopharyngeal samples. However, the current study was mainly performed in symptomatic patients and the results are not sufficiently applicable for asymptomatic patients.

There has been insufficient investigation into the diagnostic performance of antigen testing for the Omicron variant. Osterman et al. demonstrated that nine SARS-CoV-2 antigen tests commercially available in Europe showed decreased sensitivities for the Omicron variant.
Bayart also showed that six antigen tests had significantly decreased sensitivities for samples with low viral loads of Omicron variant [11]. Meanwhile, the BinaxNOW (Abbott Diagnostics Scarborough Inc., ME, USA) rapid antigen test was shown to detect 95.2% (95% CI: 91%–98%) of samples with RT-PCR Ct values <30 and 82.1% (95% CI: 77%–87%) of those with Ct values <35 during an Omicron surge period [25].

In a 2020–2021 clinical study, we evaluated the QuickNavi-COVID19 Ag test using 1934 samples. The test sensitivity was 89.3% (95% CI: 82%–94%) for symptomatic individuals and 67.1% (95% CI: 55%–78%) for asymptomatic individuals, and no false positives were observed [15]. A re-evaluation of the QuickNavi-COVID19 Ag test was performed in 1510 cases during the Delta variant dominantly circulating period in 2021, and the test sensitivity was 88.3% (95% CI: 83%–93%) for symptomatic individuals and 69.4% (95% CI: 60%–78%) for asymptomatic individuals, and three false-positive tests (0.2%) were identified [20].

The current study found a slightly better clinical performance for the QuickNavi-COVID19 Ag test during the widespread Omicron circulating period. This observed improvement could be due to the higher proportions of people with high viral loads. Meanwhile, the sensitivity of the QuickNavi-COVID19 Ag stratified by Ct values for the Omicron variant was similar to that evaluated in previous examinations [15,20]. While the sensitivity of the QuickNavi-COVID19 Ag was higher than 90% for moderate to high viral load samples (Ct < 30), the sensitivity was lower than 50% for low viral load samples (Ct ≥ 30), which was observed in both the symptomatic individuals and asymptomatic individuals. Similarly, most of false negative results were observed in low viral load samples (Ct ≥ 30). The Ct values of people who are infected with the Omicron variant are considered to be nearly the same as for previous variants; thus, it is unclear why a high proportion of participants had a high viral load [26]. In this study, the median duration from symptom onset to sample collection was 2 days and most of patients took evaluation soon after the onset of COVID-19. While the sensitivities of QuickNavi-COVID19 Ag test stratified by days from symptom onset to sample collection were higher than 90% in day 0, day1, day2, day3 and day 4–6 groups, the sensitivities were approximately 70% in day 7–9.
and day >10 groups. We considered that the early evaluations after the onset of COVID-19 attributed to the current good performance of the QuickNavi-COVID19 Ag test. Similarly, the total sensitivity of the QuickNavi-COVID19 Ag test is better than that of BinaxNow, which was performed with anterior nasal samples [25]. However, the Ct stratified sensitivity of the QuickNavi-COVID19 Ag is almost equal to that of BinaxNOW for the Omicron variant. In the analytical evaluation of BinaxNOW, anterior nasal samples were used for the evaluation and the viral load of anterior nasal samples has been reported to be much lower than that of nasopharyngeal samples [27,28], which is considered to be the gold standard and which was used in this study. We consider that the difference of the samples caused the difference in sensitivity. In this study, there are some false-negative cases among the high viral load samples (Ct < 25), which have been observed in previous antigen testing evaluations [15,16,18–20]. We considered that the results are mainly due to the differences of the viral loads of the obtained samples because the swabs for antigen testing and RT-PCR were obtained separately from different nases.

This study has some limitations. First, the samples were collected at one site in Japan, and most samples were collected soon after symptom onset. The sample size for asymptomatic individuals might have been insufficient and we did not gather detailed information on asymptomatic patients, such as the subsequent onset of COVID-19 or the number of days after close contact with an individual with COVID-19. Second, the assessment of lateral flow device results can vary among examiners [29]. Third, the reference RT-PCR examinations were performed with frozen samples, and the storage and transportation processes may have affected the test results. In addition, study samples were collected from the nasopharyngeal tract, and anterior nasal samples were not analyzed. Fourth, we performed the current evaluation only with the QuickNavi-COVID19 Ag test and we did not perform different rapid qualitative antigen tests. Additional evaluation of other rapid qualitative antigen tests is required to evaluate their sensitivity in the detection of the Omicron variant.

In conclusion, the current study showed that the QuickNavi-COVID19 Ag test had sufficient diagnostic performance for the detection of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in nasopharyngeal samples in symptomatic patients with Ct values of less than 30.

Authorship statement

All authors meet the ICMJE authorship criteria. Hiromichi Suzuki drafted the manuscript, designed the study, and supervised the collection. Shigeyuki Notake, Atsuo Ueda, and Koji Nakamura collected samples and operated the equipment. Daisuke Kato, Miwa Kuwahara and Shino Muramatsu interpreted the results. Yusaku Akashi drafted the manuscript and performed the statistical analysis. Yuto Takeuchi, Yoshihiko Kiyasu, Norihiko Terada, and Yoko Kurihara revised the manuscript. All authors contributed to the writing of the final manuscript.

Declaration of competing interest

Denka Co., Ltd. provided funds for research expenses the QuickNavi-COVID19 Ag tests without charge. Hiromichi Suzuki received a lecture fee from Otsuka Pharmaceutical Co., Ltd. Daisuke Kato, Miwa Kuwahara and Shino Muramatsu work for Denka Co., Ltd., the developer of the QuickNavi-COVID19 Ag tests.

The Ct values for RT-PCR were determined using the NIID (N gene), Japan method [22], 6 positive samples were excluded because the samples were found to be negative by the NIID method, and positive results were determined by Xpert Xpress SARS-CoV-2 and the GeneXpert System.

The Ct values for RT-PCR were determined using the NIID (N gene), Japan method [22], 5 positive samples were excluded because the samples were found to be negative by the NIID method, and positive results were determined by Xpert Xpress SARS-CoV-2 and the GeneXpert System.

The Ct values for RT-PCR were determined using the NIID (N2 gene), Japan method [22], 1 positive sample was excluded because the samples were found to be negative by the NIID method, and positive results were determined by Xpert Xpress SARS-CoV-2 and the GeneXpert System.

Acknowledgments

We thank Ms. Yoko Ueda, Ms. Mio Matsumoto, Mr. Masaomi Matsubayashi, Ms. Mika Yaguchi, Ms. Yumiko Tanaka, Mr. Naoki Tanimura, and the staff of the Department of Clinical Laboratory of Tsukuba Medical Center Hospital for their support in this study. We thank all participating medical institutions for providing their patients’ clinical information.

References

[1] Backer JA, Eggingk D, Andeweg SP, Veldhuijzen IK, van Maarenveen N, Vermaas K, et al. Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, The Netherlands. Euro Surveill 2021;27:13–26. 2022.
[2] Cheng VC, Ip JD, Chu AW, Tam AR, Chan WM, Abdullah SMU, et al. Rapid spread of SARS-CoV-2 Omicron subvariant BA.2 in a single-source community outbreak. Clin Infect Dis 2022;75:544–9.
[3] Lee HR, Cho YJ, Jung EJ, Kim J, Lee JJ, Lee HY, et al. Time to exposure from diagnosis among quarantined close contacts of SARS-CoV-2 omicron variant index case-patients, South Korea. Emerg Infect Dis 2022;28:901–3.
[4] Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 2022;603:679–86.
[5] Andrews N, Stone J, Kirssebohm F, Toffa S, Rickard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med 2022;386:1532–46.
[6] Tseng HF, Ackerson BK, Loo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. Nat Med 2022;28:1453–71.
[7] World Health Organization. Weekly epidemiological update on COVID-19 - 17 April 2022, 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19, 27-april-2022 [Accessed 9 May].
[8] Hui KPY, Ho JCW, Cheng MC, Ng KC, Ching RH, Lai KL, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 2022;603:715–20.
[9] Menni C, Valdes AM, Polidori I, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet 2022;399:1618–24.
[10] World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. https://www.who.int/publications/i/item/ antigen-detection-in-the-diagnosis-of-sars-cov-2-infection-using-rapid-immunoassays.
[11] Bayart JI, Degrosier J, Favresse J, Gillot C, Didembourg M, Dijokto HP, et al. Analytical sensitivity of six SARS-CoV-2 rapid antigen tests for omicron versus delta variant. Viruses 2022;14:654.
[12] Osterman A, Badell I, Basara E, Stern M, Kriesel F, Eletreby M, et al. Impaired detection of omicron by SARS-CoV-2 rapid antigen tests. Med Microbiol Immunol 2022;211:105–17.
[13] Kiyasu Y, Akashi Y, Sugiyama A, Takeuchi Y, Notake S, Naito A, et al. A prospective evaluation of the analytical performance of GENECUBE(R) HQ SARS-CoV-2 and GENECUBE(R) FLU A/B. Mol Diagn Ther 2021;25:495–504.
[14] Kiyasu Y, Owaku M, Akashi Y, Takeuchi Y, Naráhara K, Mori S, et al. Clinical evaluation of the rapid nucleic acid amplification point-of-care test (Smart Gene SARS-CoV-2) in the analysis of nasopharyngeal and anterior nasal samples. J Infect Chemother 2022;28:543–7.
[15] Kiyasu Y, Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, et al. Prospective analytical performance evaluation of the QuickNavi-COVID19 Ag for asymptomatic individuals. J Infect Chemother 2021;27:489–92.
[16] Kuribara Y, Kiyasu Y, Akashi Y, Takeuchi Y, Nararahara K, Mori S, et al. The evaluation of a novel digital immunochromatographic assay with silver amplification to detect SARS-CoV-2. J Infect Chemother 2021;27:1493–9.
[17] Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen. N Engl J Med 2020;382:e76.
[18] Suzuki H, Akashi Y, Ueda A, Kiyasu Y, Takeuchi Y, Maehara Y, et al. Diagnostic performance of a novel digital immunoassay (RapidTest SARS-CoV-2): a prospective observational study with nasopharyngeal samples. J Infect Chemother 2022;28:78–81.
[19] Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, et al. The evaluation of a newly developed antigen test (QuickNavi-COVID19 Ag) for SARS-CoV-2: a prospective observational study in Japan. J Infect Chemother 2021;27:890–4.
[20] Takeuchi Y, Akashi Y, Kiyasu Y, Terada N, Kurihara Y, Kato D, et al. A prospective evaluation of diagnostic performance of a combo rapid antigen test QuickNavi-Flu-COVID19 Ag. J Infect Chemother 2022;28:940–3.

[21] Naito A, Kiyasu Y, Akashi Y, Sugiyama A, Michibuchi M, Takeuchi Y, et al. The evaluation of the utility of the GENECUBE HQ SARS-CoV-2 for anterior nasal samples and saliva samples with a new rapid examination protocol. PLoS One 2023;16:e0262159.

[22] Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Development of genetic diagnostic methods for detection for novel coronavirus 2019 (nCoV-2019) in Japan. Jpn J Infect Dis 2020;73:304–7.

[23] Loeffelholz MJ, Alland D, Butler-Wa SM, Pandey U, Perno CF, Nava A, et al. Multicenter evaluation of the cepheid Xpert xpress SARS-CoV-2 test. J Clin Microbiol 2020;58. e00926-20.

[24] Ibaraki Prefectural Government. Laboratory data for COVID-19. https://www.pref.ibaraki.jp/hokenfukushi/eiken/kikaku/documents/singatakorona0711.pdf. [Accessed 18 July 2022]. Accessed.

[25] Schrom J, Marquez C, Pilarowski G, Wang CY, Mitchell A, Puccinelli R, et al. Comparison of SARS-CoV-2 reverse transcriptase polymerase chain reaction and BinaxNOW rapid antigen tests at a community site during an omicron surge: a cross-sectional study. Ann Intern Med 2022;175:682–90.

[26] Laitman AM, Lieberman JA, Hoffman NG, Roychoudhury P, Mathias PC, Greninger AL. The SARS-CoV-2 omicron variant does not have higher nasal viral loads compared to the delta variant in symptomatic and asymptomatic individuals. J Clin Microbiol 2022;60:e001922.

[27] Akashi Y, Horie M, Kiyotaki J, Takeuchi Y, Togashi K, Adachi Y, et al. Clinical performance of the cobas list SARS-CoV-2 & influenza A/B assay in nasal samples. Mol Diagn Ther 2022;26:323–31.

[28] Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, et al. Diagnostic performance and characteristics of anterior nasal collection for the SARS-CoV-2 antigen test: a prospective study. Sci Rep 2021;11:10519.

[29] Peto T, Team UC-LFO. COVID-19: rapid antigen detection for SARS-CoV-2 by lateral flow assay: a national systematic evaluation of sensitivity and specificity for mass-testing. eClinicalMedicine 2021;36:100924.